Advanced Search

2022 Vol. 4, No. 50

Preplanned Studies
Declines in Blood Lead Levels Among General Population — China, 2000–2018
Yuebin Lyu, Jing Chen, Zheng Li, Liang Ding, Feng Zhao, Yingli Qu, Xulin Zheng, Zheng Zhang, Xiaojian Hu, Saisai Ji, Yifu Lu, Yawei Li, Yuanduo Zhu, Yanwei Yang, Yidan Qiu, Haocan Song, Wenli Zhang, Bing Wu, Jiayi Cai, Miao Zhang, Fangyu Li, Ying Zhu, Zhaojin Cao, John Ji, Xiaoyuan Yao, Yuxin Zheng, Xiaoming Shi
2022, 4(50): 1117-1122. doi: 10.46234/ccdcw2022.226
Abstract(3733) HTML (128) PDF 1380KB(67)
Abstract:
What is already known about this topic?

Environmental and occupational lead exposure has generally declined in the past two decades. However, there is no large-scale monitoring of blood lead levels (BLLs) in the Chinese general population.

What is added by this report?

This nationally representative study showed declines of BLLs in all ages of participants; for children aged 3–5 years, down from 78.1 μg/L to 16.9 μg/L, corresponding to 78.4% decrease in the past two decades (2000–2018).

What are the implications for public health practice?

Recommendations for elevated BLLs on screening children at high risk now need to be revisited and updated from 100 μg/L to 50 μg/L in guidelines to conform with the substantial declines in China.

Incidence and Risk Factors of the Upper-Limb Musculoskeletal Disorders Among Occupational Groups in Key Industries — China, 2018–2021
Ning Jia, Meibian Zhang, Huadong Zhang, Ruijie Ling, Yimin Liu, Gang Li, Yan Yin, Hua Shao, Hengdong Zhang, Bing Qiu, Dongxia Li, Dayu Wang, Qiang Zeng, Rugang Wang, Jianchao Chen, Danying Zhang, Liangying Mei, Xinglin Fang, Yongquan Liu, Jixiang Liu, Chengyun Zhang, Tianlai Li, Jun Qi, Qing Xu, Ying Qu, Xueyan Zhang, Xin Sun, Zhongxu Wang
2022, 4(50): 1123-1130. doi: 10.46234/ccdcw2022.227
Abstract(3564) HTML (206) PDF 259KB(52)
Abstract:
What is already known about this topic?

The burden of illness and economic losses due to upper-limb work-related musculoskeletal disorders (UL-WMSDs) is high; thus, they have become a major global public health problem. At present, the epidemiological characteristics of UL-WMSDs in China's occupational population are still unknown.

What is added by this report?

The incidence of UL-WMSDs among key occupational groups in China is 22.5%, with distinct occupational characteristics.

What are the implications for public health practice?

This study has primarily determined the occurrence and potential risk factors of UL-WMSDs in key industries in China and provided data support for recommending prevention and control of the occurrence of such diseases in key industries in China, and in facilitating the addition into the China’s List of Legal Occupational Diseases.

Characteristics and Containment of 74 Imported COVID-19 Outbreaks: Experiences, Lessons, and Implications — China, 2020–2021
Fuxiao Li, Chang Wei, Bingli Li, Tengfei Lin, Yiwen Jiang, Di Liu, Zhirong Yang, Zuyao Yang, Feng Sha, Jinling Tang
2022, 4(50): 1131-1135. doi: 10.46234/ccdcw2022.228
Abstract(3482) HTML (100) PDF 1043KB(81)
Abstract:
What is already known about this topic?

After the initial coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China, the outbreaks during the dynamic-zero policy period in the mainland of China have not been systematically documented.

What is added by this report?

We summarized the characteristics of 74 imported COVID-19 outbreaks between March 19, 2020 and December 31, 2021. All outbreaks of early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants were successfully contained with the aid of nucleic acid testing, modern communication technologies, and non-pharmacological interventions.

What are the implications for public health practice?

These findings provide us with confidence for the containment of future emerging infectious diseases alike at early stages to prevent pandemics or to win time to gain experience, develop vaccines and drugs, vaccinate people, and wait for the possible lessening of the virus’ pathogenicity.

Vital Surveillances
Surveillance and Analysis of SARS-CoV-2 Variant Importation — China, January–June 2022
Yenan Feng, Xiang Zhao, Zeyuan Yin, Changcheng Wu, Zhixiao Chen, Kai Nie, Ruhan A, Lili Li, Peihua Niu, Ji Wang, Yuchao Wu, Shiwen Wang, Dayan Wang, Wenjie Tan, Huanyu Wang, Xuejun Ma, George F. Gao, Cao Chen, Wenbo Xu
2022, 4(50): 1136-1142. doi: 10.46234/ccdcw2022.229
Abstract(4234) HTML (136) PDF 553KB(71)
Abstract:
Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is the dominant circulating strain worldwide. To assess the importation of SARS-CoV-2 variants in the mainland of China during the Omicron epidemic, the genomic surveillance data of SARS-CoV-2 from imported coronavirus disease 2019 (COVID-19) cases in the mainland of China during the first half of 2022 were analyzed.

Methods

Sequences submitted from January to July 2022, with a collection date before June 30, 2022, were incorporated. The proportions of SARS-CoV-2 variants as well as the relationships between the origin and destination of each Omicron imported case were analyzed.

Results

4,946 sequences of imported cases were submitted from 27 provincial-level administrative divisions (PLADs), and the median submission interval was within 1 month after collection. In 3,851 Omicron sequences with good quality, 1 recombinant (XU) and 4 subvariants under monitoring (BA.4, BA.5, BA.2.12.1, and BA.2.13) were recorded, and 3 of them (BA.4, BA.5, and BA.2.12.1) caused local transmissions in the mainland of China later than that recorded in the surveillance. Omicron subvariants dominated in the first half of 2022 and shifted from BA.1 to BA.2 then to BA.4 and BA.5. The percentage of BA.2 in the imported SARS-CoV-2 surveillance data was far higher than that in the Global Initiative on Sharing All Influenza Data (GISAID). The imported cases from Hong Kong Special Administrative Region, China, accounted for 32.30% of Omicron cases sampled, and 98.71% of them were BA.2.

Conclusions

The Omicron variant showed the intra-Omicron evolution in the first half of 2022, and all of the Omicron subvariants were introduced into the mainland of China multiple times from multiple different locations.